Stephanie K Lynch1, Kyungmoo Lee2, Zhi Chen2, James C Folk1,3, Ursula Schmidt-Erfurth4, Bianca S Gerendas4, Andreas Wahle2, Charles C Wykoff5, Michael D Abràmoff1,2,3,6,7. 1. Department of Ophthalmology and Visual Sciences, University of Iowa, Carver College of Medicine, Iowa City, Iowa, United States. 2. Department of Electrical and Computer Engineering, University of Iowa, Iowa City, Iowa, United States. 3. IDx, Coralville, Iowa, United States. 4. Department of Ophthalmology and Optometry, Vienna Reading Center, Medical University of Vienna, Vienna, Austria. 5. Retina Consultants of Houston, Blanton Eye Institute, Houston, Texas, United States. 6. Iowa Institute for Vision Research, Iowa City, Iowa, United States. 7. Veterans Affairs Medical Center, Iowa City, Iowa, United States.
Abstract
Purpose: There is no prevention or treatment for diabetic retinal neurodegeneration (DRN), which is a complication of diabetes that can occur independently of diabetic retinopathy (DR). We hypothesized that an intravitreal fluocinolone acetonide (FAc) implant may affect the rate of DRN when used in patients with diabetic macular edema (DME). Methods: In this retrospective analysis, optical coherence tomography with neuroretinal analysis was obtained at 3-month intervals from 130 patients in the USER study both before (mean duration 903 days, range 35-4005 days) and after administration of FAc (mean 408 days, range 7 to 756 days). The rate of DRN was defined as the change over time on inner neuroretinal thickness using logistic regression. A DRN rate was calculated independently for two areas: region 1 located within 1.5 mm of the fovea, and region 2 from 1.5 mm to 3.0 mm from the fovea. Results: In regions of the macula more than 1.5 mm from the central fovea, there was a statistically significant decrease in the rate of DRN in the post-FAc period. The pre-FAc neuroretinal loss in this area occurred at 4.0 μm/y, compared with a post-FAc loss rate of 1.1 μm/y (P = 0.001). Conclusions: This retrospective study suggests that FAc may decelerate the rate of inner retinal thinning in patients with persistent DME. Further prospective studies are necessary to determine the effects of FAc on the rate of DRN in patients with DME.
Purpose: There is no prevention or treatment for diabetic retinal neurodegeneration (DRN), which is a complication of diabetes that can occur independently of diabetic retinopathy (DR). We hypothesized that an intravitreal fluocinolone acetonide (FAc) implant may affect the rate of DRN when used in patients with diabetic macular edema (DME). Methods: In this retrospective analysis, optical coherence tomography with neuroretinal analysis was obtained at 3-month intervals from 130 patients in the USER study both before (mean duration 903 days, range 35-4005 days) and after administration of FAc (mean 408 days, range 7 to 756 days). The rate of DRN was defined as the change over time on inner neuroretinal thickness using logistic regression. A DRN rate was calculated independently for two areas: region 1 located within 1.5 mm of the fovea, and region 2 from 1.5 mm to 3.0 mm from the fovea. Results: In regions of the macula more than 1.5 mm from the central fovea, there was a statistically significant decrease in the rate of DRN in the post-FAc period. The pre-FAc neuroretinal loss in this area occurred at 4.0 μm/y, compared with a post-FAc loss rate of 1.1 μm/y (P = 0.001). Conclusions: This retrospective study suggests that FAc may decelerate the rate of inner retinal thinning in patients with persistent DME. Further prospective studies are necessary to determine the effects of FAc on the rate of DRN in patients with DME.
Authors: Inna V Glybina; Alexander Kennedy; Paul Ashton; Gary W Abrams; Raymond Iezzi Journal: Invest Ophthalmol Vis Sci Date: 2010-03-10 Impact factor: 4.799
Authors: Hrvoje Bogunović; Young H Kwon; Adnan Rashid; Kyungmoo Lee; Douglas B Critser; Mona K Garvin; Milan Sonka; Michael D Abràmoff Journal: Invest Ophthalmol Vis Sci Date: 2014-12-09 Impact factor: 4.799
Authors: Mona Kathryn Garvin; Michael David Abràmoff; Xiaodong Wu; Stephen R Russell; Trudy L Burns; Milan Sonka Journal: IEEE Trans Med Imaging Date: 2009-03-10 Impact factor: 10.048
Authors: Elliott H Sohn; Hille W van Dijk; Chunhua Jiao; Pauline H B Kok; Woojin Jeong; Nazli Demirkaya; Allison Garmager; Ferdinand Wit; Murat Kucukevcilioglu; Mirjam E J van Velthoven; J Hans DeVries; Robert F Mullins; Markus H Kuehn; Reinier Otto Schlingemann; Milan Sonka; Frank D Verbraak; Michael David Abràmoff Journal: Proc Natl Acad Sci U S A Date: 2016-04-25 Impact factor: 11.205
Authors: Hille W van Dijk; Pauline H B Kok; Mona Garvin; Milan Sonka; J Hans Devries; Robert P J Michels; Mirjam E J van Velthoven; Reinier O Schlingemann; Frank D Verbraak; Michael D Abràmoff Journal: Invest Ophthalmol Vis Sci Date: 2009-01-17 Impact factor: 4.799
Authors: Jennifer K Sun; Salma H Radwan; Ahmed Z Soliman; Jan Lammer; Michael M Lin; Sonja G Prager; Paolo S Silva; Lloyd Bryce Aiello; Lloyd Paul Aiello Journal: Diabetes Date: 2015-01-29 Impact factor: 9.461
Authors: Jacoba A van de Kreeke; Stanley Darma; Jill M P L Chan Pin Yin; H Stevie Tan; Michael D Abramoff; Jos W R Twisk; Frank D Verbraak Journal: PLoS One Date: 2020-04-16 Impact factor: 3.240